Clostridium chauvoei vaccine, inactivated, as a veterinary-grade active pharmaceutical ingredient for tablets, injections, capsules, powders, granules, premixes and solutions is supplied as a formalin-inactivated whole culture of a defined C. chauvoei strain, processed into either a lyophilised powder or a liquid antigen concentrate. The material is intended solely as an antigen intermediate for further formulation into finished veterinary dosage forms; it is not a ready-to-administer immunisation product. Two standard model designations are available: CCV-API-LYO-250, a freeze-dried cake with residual moisture controlled to ≤2.0% w/w, and CCV-API-SUS-100, an aluminium hydroxide-adjuvanted liquid concentrate. Compendial alignment is maintained with Ph. Eur. 0361 and, for products destined to the United States, 9 CFR 113.108. Because C. chauvoei is a spore-forming anaerobic bacterium, the manufacturing process must control sporulation during fermenter growth; uncontrolled spore formation changes downstream filterability, antigen release and the protective index in potency testing.

Microbial Identity, Inactivation Chemistry and Antigenic Consistency Requirements

The API is derived from a master seed lot that is passaged under anaerobic conditions and characterised by 16S rRNA sequence, clostridial species-specific PCR, and slide agglutination with monospecific antiserum. Production fermentation is performed in stirred-tank bioreactors fitted with Rushton turbines, with pH maintained at 7.0–7.4 and temperature at 37 °C. Harvest is taken at late logarithmic growth before substantial sporulation; spore counts are monitored by phase-contrast microscopy and malachite green differential staining. Inactivation is achieved with formaldehyde at 0.3%–0.5% v/v for 48–72 h at 37 °C, followed by diafiltration to remove excess aldehyde. The lyophilised product is standardised by total antigenic protein and potency relative to a homologous reference vaccine; total antigenic protein is normally reported on the certificate of analysis, with the compendial potency test remaining the release-limiting assay. Batch-to-batch variance is controlled by holding the fermenter redox potential below −300 mV and by maintaining a defined agitation profile; deviations in agitation alter the ratio of surface-layer to flagellar antigens and can shift the protective index in the guinea pig challenge model.

Primary packaging for CCV-API-LYO-250 consists of Type I glass vials with bromobutyl rubber stoppers and aluminium flip-off seals. Lyophilised vials are sealed under vacuum or nitrogen with headspace oxygen controlled to ≤2.0% v/v. The liquid presentation CCV-API-SUS-100 is filled aseptically into sterile polypropylene or glass containers and stored at 2–8 °C; freezing is prohibited because freeze-thaw cycles dissociate aluminium hydroxide floccules and release antigen into the supernatant.

What Limits Direct Compression of Lyophilised API in Oral Solid Dosage Forms?

Direct compression of model CCV-API-LYO-250 into tablets is governed by the thermomechanical stability of the freeze-dried matrix rather than by antigen potency alone. The lyophilised cake is often composed of trehalose or mannitol as a lyoprotectant, with an amorphous fraction that can undergo structural collapse if the product temperature exceeds the critical collapse temperature during secondary drying. For direct compression, the powder is dry-blended with microcrystalline cellulose or lactose monohydrate in a bin blender; blend uniformity requires a relative standard deviation of antigen content not exceeding 5.0%. Compression on a rotary tablet press should use precompression to remove entrapped air and a main compression force that does not raise tablet surface temperature above 40 °C. The main compression force is formulation-specific, commonly in the range 8–12 kN for a 9 mm flat-faced bevel-edged tool, but published data for this specific configuration is limited. Powder flow properties should be assessed by a shear cell method such as ASTM D6128-16; lyophilised cakes with low bulk density and flow function coefficients below 2.0 indicate cohesive flow and require glidant addition. Moisture uptake during handling must be controlled; if relative humidity exceeds 60%, the lyophilised powder may become sticky and lose compressibility. Capsule filling of the powder into hypromellose capsules can reduce compression stress but introduces a slower dissolution step; the antigen must be protected from gastric acid by an enteric coating or by filling into hard capsules coated with an enteric polymer.

When Granulation Is Required for Premix Uniformity, Binder Selection Must Avoid Aldehyde Scavengers

Granules and premixes containing inactivated C. chauvoei API are produced when the antigen is intended for oral administration through feed or drinking water. Wet granulation is less suitable for highly water-soluble lyoprotected powders because local dissolution and re-drying can denature surface antigens. If a granulation step is unavoidable, a fluidised-bed top-spray process with inlet air temperature not exceeding 35 °C and product temperature below 30 °C is used. Binder selection is constrained by residual formaldehyde and the antigen surface chemistry; gelatin, lysine-containing amino acids, and primary amine-functional polymers should be avoided because they may scavenge residual formaldehyde and alter the antigen-protein crosslinking equilibrium. Hydroxypropyl methylcellulose or polyvinyl acetate-based binders are considered lower-risk alternatives. Granule size distribution is controlled through sieve analysis; a typical target is 180–850 µm for feed premix to ensure blend uniformity. Premix uniformity is validated by sampling at multiple time points in a double-cone or ribbon blender, with antigen content tested by ELISA; the acceptance limit is a relative standard deviation ≤5.0%. The API for solutions is prepared as a reconstituted suspension immediately before use, because aqueous stability at ambient temperature is limited; continuous medication in drinking water is not recommended unless the final solution is buffered to pH 6.5–7.0 and used within 4 h.

Injectable Adjuvant Compatibility and Sterile Manufacturing Boundaries

Adjuvant selection for injectable formulations is constrained by the surface charge of the formalin-inactivated whole cells. Aluminium hydroxide gel at 1.0%–2.0% w/v is the standard adsorption matrix; adsorption efficiency is pH-dependent, with maximum antigen binding generally observed between pH 6.5 and 7.5. The addition of aluminium phosphate changes the zeta potential and can reduce binding if the antigen is negatively charged at neutral pH. Sterile filling of final injectable suspensions must occur under ISO 14644-1:2015 class 5 conditions with terminal sterilisation not applicable; therefore sterility assurance rests on aseptic processing and pre-filtration sterilisation of the antigen concentrate through a 0.22 µm membrane. The liquid concentrate should not be frozen; storage is at 2–8 °C. In-use stability after first opening should be established in the marketing authorisation; without such data, opened containers should be used within 8 h.

Finished vaccines prepared from this API are used for active immunisation of cattle and sheep against blackleg. In many jurisdictions, primary vaccination consists of two doses administered 4–6 weeks apart, followed by annual booster; this clinical usage pattern must be confirmed by local marketing authorisation and product-specific challenge data. The final injectable suspension may be administered subcutaneously or intramuscularly according to the approved label.

How the Inactivated C. chauvoei API Differs from Clostridial Toxoid and Multivalent Vaccine Intermediates

The C. chauvoei API is a whole-cell bacterin, not a toxoid. Unlike Clostridium perfringens type D epsilon toxoid or Clostridium novyi alpha toxoid, the protective antigen complex of C. chauvoei is not reduced to a single soluble exotoxin; protection in the guinea pig challenge model correlates with multiple cell-associated antigens, including surface-layer proteins and flagellar components. This distinction limits the use of simple ultrafiltration-based potency markers such as Lf/mL toxoid flocculation; antigen concentration must be standardised by a functional challenge test or a validated antigen-capture ELISA linked to the challenge method. When the API is blended into multivalent clostridial vaccines, the antigen load per dose can interact with separate toxoid components; aluminium hydroxide capacity must be verified by adsorption assays, and free antigen in the supernatant must remain below the release limit. Compared with C. septicum and C. sordellii bacterins, C. chauvoei cultures typically produce more gas and require stricter foam control during fermentation; antifoam selection must avoid silicone oil carryover into the final sterile filtrate. For oral dosage forms, the C. chauvoei whole-cell antigen is more resistant to gastric acid than soluble toxoids, but oral administration is not a standard route; published efficacy data for this specific configuration is limited and regulatory acceptance requires local challenge studies.

For powders, granules and premixes, the C. chauvoei API should not be combined with gelatin capsules or gelatin-based binders because residual formaldehyde can crosslink the capsule wall and retard disintegration. The oral solid-dose route remains non-compendial for this antigen; development work must include forced degradation studies under 40 °C / 75% relative humidity according to ICH Q1A or regionally accepted stability guidelines to justify any label claim.